Deluche et al. investigated real-world outcomes for ER-positive/HER2-negative metastatic BC, reporting a median OS of 43.3 months (95% CI: 42.5–44.5) for 22000 patients treated between 2008 to 2016, predating CDK 4/6i use [3]. Here, ERBB2 is linked to breast cancer.